Day 2 :
Keynote Forum
Isaura Meza
CINVESTAV, Mexico
Keynote: Role of the proinflammatory cytokine IL-1β in breast cancer progression to malignancy
Biography:
In the tumor inflammatory microenvironment, interleukin-1β (IL-1β) has been associated with tumor development, invasiveness, metastasis and initiation of the epithelial to mesenchymal transition (EMT). Using a model of breast cancer non-invasive cells, we have recently demonstrated that IL-1β triggers the activation of a signaling pattern, not previously described, named as IL-1β/IL-1RI/β-catenin that induces accumulation of β-catenin in the nucleus and GSK1 inactivation by AKT phosphorylation. Translocation of β-catenin to the nucleus and formation of the TCF/Lef/β-catenin complex causes sequential expression of genes that leads to up-regulation of cell proliferation, migration and invasion. By the activation of these processes, the IL-1β-stimulated cells enter the transition program, from a non-invading to an invading phenotype, known as EMT. Initial results on a selected MCF-7 cell clone (6D) highly sensitive to IL-1β showed that IL-1β up-regulated SNAIL, c-MYC and MMP2, genes involved in replication and invasion. Subsequent RNA-seq showed direct correlation between upregulation of cell survival and drug resistance genes such as BIRC3, CDKN1A, TP63 and BCL2. Our results with this 6D cell model, in which EMT has been induced by IL-1β, showed that methylation of the ESR1 promoter occurred as consequence of the up-regulation of TWIST1 through the cytokine activated pathway, leading to decreased levels of the oestrogen receptor ERα, as observed in aggressive breast cancer tumors classified as triple negative. We hope that our results showing some of the mechanisms by which an inflammatory environment influences malignancy will draw attention to this aspect of cancer pathology and the possibility for using new therapeutic schemes in its treatment.
Abstract:
Keynote Forum
Maru Barrera
Dept. of Psychology and Division of Hematology/ Oncology, Canada
Keynote: Why is early psychosocial screening important in pediatric cancer?
Time : 10.15-10.55
Biography:
Abstract:
- Cancer Therapeutics | Cancer Nursing | Cancer Biology | Cancer Management & Prevention
Location: Descobrimentos
Chair
Robert Thomas
Bedford and Addenbrooke’s Cambridge University Hospitals, UK
Co-Chair
Shanmugasundaram Ganapathy Kanniappan
Johns Hopkins University, USA
Session Introduction
Shanmugasundaram Ganapathy Kanniappan
Johns Hopkins University, USA
Title: Tumor glycolysis-The stygian link between two hallmarks of cancer and novel therapeutic opportunities
Biography:
Abstract:
Qi-Fei Wang
The First Affiliated Hospital of Dalian Medical University
Title: Using 'zero-ischemia' and 'sutureless' techniques to implement laparoscopic partial nephrectomy with holmium laser
Biography:
Abstract:
Biography:
Abstract:
Biography:
Abstract:
Robert Thomas
Bedford and Addenbrooke’s Cambridge University Hospitals, UK
Title: Lifestyle after cancer to reduce toxicity and improve outcomes – What evidence based strategies should we advise patients?
Biography:
Abstract:
Sonia A Melo
University of Porto, Portugal
Title: Communication network mediated by exosomes as a new therapeutic target for pancreatic cancer
Biography:
Abstract:
- Young Researchers Forum
Location: Descobrimentos
Session Introduction
Zofia Felicja Bielecka
Warsaw Medical University, Poland
Title: Protein expression profiling of sorafenib-resistant human renal cancer stem-like cells in three-dimensional in vitro model
Biography:
Abstract:
Mahmood Faraz
Umea University, Sweden
Title: Identification and functional evaluation of LRIG1-interacting proteins
Biography:
Mahmood Faraz is a PhD student in Umea University, Sweden.
Abstract:
Carolina F Ruivo
University of Porto, Portugal
Title: ExoNet - Intratumor communication network mediated by exosomes in pancreatic cancer
Biography:
Abstract:
Nuno Bastos
University of Porto, Portugal